SEARCH

SEARCH BY CITATION

References

  • 1
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:20772082.
  • 2
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:15351541.
  • 3
    Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9:461468.
  • 4
    Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB 1997 Treatment with alendronate prevents fractures in women at highest risk: Results from the Fracture Intervention Trial. Arch Intern Med 157:26172624.
  • 5
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:16931700.
  • 6
    Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Monaco R, Gennari C 1997 The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res 12:624631.
  • 7
    Bauer DC, Sklarin PM, Stone KL, Black DM, Nevitt MC, Ensrud KE, Arnaud CD, Genant HK, Garnero P, Delmas PD, Lawaetz H, Cummings SR 1999 Biochemical markers of bone turnover and prediction of hip bone loss in older women: The study of osteoporotic fractures. J Bone Miner Res 14:14041410.
  • 8
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB 1998 Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res 13:14311438.
  • 9
    Rosen CJ, Chesnut CH III, Mallinak NJ 1997 The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82:19041910.[see comments]
  • 10
    Chesnut CH III, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC Jr, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ 1997 Hormone replacement therapy in postmenopausal women: Urinary N- telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102:2937.
  • 11
    Seibel MJ, Naganathan V, Barton I, Grauer A 2004 Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19:323329.
  • 12
    Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR 1993 Design of the Fracture Intervention Trial. Osteoporos Int 3(Suppl 3):S29S39.
  • 13
    Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH 2000 Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 11:467480.
  • 14
    Garnero P, Delmas PD 1993 Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77:10461053.
  • 15
    Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J 1996 Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 46:947954.
  • 16
    Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C 1998 Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:22812289.
  • 17
    Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD 2000 Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: The EPIDOS study. Bone 27:283286.
  • 18
    Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A 2004 Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34:187194.
  • 19
    Genant HK, Wu CY, Van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:11371148.
  • 20
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:41184124.
  • 21
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:15261536.
  • 22
    Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C 1988 Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment. J Clin Invest 82:12681274.
  • 23
    Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Montagnani A, Monaco R, Gennari C 1999 Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 65:359364.
  • 24
    Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial. J Bone Miner Res 19:12501258.
  • 25
    Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337349.
  • 26
    Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA 2000 Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study. Osteoporos Int 11:7682.
  • 27
    Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Vaananen HK, Akesson K, Obrant KJ 2004 Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386393.
  • 28
    National Osteoporosis Foundation 1998 Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness snalysis: Status report. Osteoporos Int 8(Suppl 4):S1S88.
  • 29
    Anonymous 2002 Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 137:526528.
  • 30
    Cheung AM, Feig DS, Kapral M, Diaz-Granados N, Dodin S 2004 Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: Recommendation statement from the Canadian Task Force on Preventive Health Care. Can Med Assoc J 170:16651667.
  • 31
    Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML 2004 Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:11081112.
  • 32
    Schuit SC, Van Der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, Van Leeuwen JP, Pols HA 2004 Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone 34:195202.
  • 33
    Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR 2003 BMD at multiple sites and risk of fracture of multiple types: Long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18:19471954.